M.G. Davies, M.D.,
Ph.D., M.B.A.

CRITICAL LIMB ISCHEMIA: EPIDEMIOLOGY

Mark G. Davies, M.D., Ph.D., M.B.A.

Methodist DeBakey Heart & Vascular Center, The Methodist Hospital, Houston, Texas

Abstract

Critical limb ischemia is found in 12% of the U.S. adult population. Its clinical presentation varies from no symptoms to intermittent claudication, atypical leg pain, rest pain, ischemic ulcers, or gangrene. Those with critical limb ischemia have a high incidence of cardiovascular comorbidities that reflect a significant systemic atherosclerotic burden; they have increased functional impairment and increased rates of functional decline compared with persons without critical limb ischemia. Interventions for critical limb ischemia and the impact of major amputation have a significant social and economic impact. At 1 year, 25% of patients will be dead, 30% will have undergone amputation, and only 45% will remain alive with both limbs. At 5 years, more than 60% of patients with critical limb ischemia will be dead.

Introduction

Eight to ten million Americans suffer from arterial occlusive disease, leading to approximately 500–1,000 new cases of chronic limb ischemia per million people per year.¹ The prevalence of critical limb ischemia is 12% in the adult population, with men affected slightly more than women. This prevalence is age-dependent as well, with nearly 20% of adults age 70 and older carrying a diagnosis of critical limb ischemia. As the population ages, the impact of this disease on health care will be magnified. The PARTNERS (PAD Awareness, Risk, and Treatment: New Resources for Survival) study found critical limb ischemia present in 29% of the study patients aged 70 years and older and aged 50 to 69 years with at least a 10-pack-per-year history of smoking or a history of diabetes.² Greater than 70% of primary care providers in the PARTNERS study were unaware of the presence of critical limb ischemia in their patients who had the disease. Coexistent coronary artery disease (CAD) and cerebrovascular disease (CVD) are highly prevalent (63%) in patients with critical limb ischemia, particularly in the elderly population. Patients over the age of 50 with critical limb ischemia in an academic, hospital-based geriatric practice have a 68% and 42% incidence of coexistent CAD and stroke, respectively.³ The Reduction of Atherothrombosis for Continued Health (REACH) registry showed that one of six patients with peripheral arterial disease (PAD), CVD, or CAD had involvement of one or two other arterial beds.^{4,5} The REACH registry also demonstrated a substantial gap between recommended clinical guidelines and actual clinical practices in caring for patients with or at risk for atherothrombosis. A pattern of underutilization of established medical therapies and lifestyle interventions was shown throughout all geographic regions studied and vascular disease subtypes.⁴

Chronic limb ischemia reflects the local manifestations of a lethal systemic disease — atherosclerosis. If left untreated, chronic limb ischemia can result in major limb loss. Critical limb ischemia can be separated into four distinct cohorts: asymptomatic, claudication, critical limb ischemia with rest pain, and critical limb ischemia with tissue loss. The natural history of critical limb ischemia is well documented. At 1 year, 25% of patients will be dead, 30% will have undergone amputation, and 45% will be

Figure 1. 10-year survival in patients with asymptomatic and symptomatic peripheral arterial disease.

alive with both limbs.¹ More than 60% of patients with critical limb ischemia will be dead at 5 years.⁶ Patients with critical limb ischemia are at an exceptionally high risk for cardiovascular events, and the majority will eventually die of a cardiac or cerebrovascular event. The more symptomatic and severe the critical limb ischemia as objectively measured by the ankle-brachial index (ABI), the worse the overall patient prognosis (Figure 1). In the REACH registry, the relative risk of dying among patients with large-vessel critical limb ischemia versus none was 3.1 (95% CI 1.9–4.9) for deaths from all causes and 5.9 (95% CI 3.0–11.4) for all deaths from cardiovascular disease. Mortality due to cardiovascular disease was 15-fold higher among symptomatic subjects with severe large-vessel critical limb ischemia. Finally, critical limb ischemia has been classified as a coronary heart disease (CHD) risk equivalent (i.e., carrying >20% risk of a coronary event in 10 years).

The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001)⁷ classified diabetes, multiple cardiac risk factors, and critical limb ischemia, including carotid disease and abdominal aortic aneurysm, as a CHD risk equivalent. The epidemic of diabetes and metabolic syndrome has escalated the number of lower-extremity problems presenting

for treatment. It has been estimated that 50% of diabetic patients have evidence of chronic critical limb ischemia.⁸ Diabetics suffer from both micro- and macro-vascular disease of complex etiology, manifested often as ischemia but more frequently as motor or sensory neuropathies.⁹ Globally, diabetes accounts for 1 amputation every 30 seconds and 80,000 amputations annually in the United States alone. Fifty percent of these patients will have an above- or below-knee amputation, 50% will require a second amputation within 5 years, and 50% will be dead in five years. Of those patients presenting with critical limb ischemia, 67% undergo a primary amputation, and 50% of these are performed without imaging or noninvasive testing. Of these amputations, 85% are considered preventable.⁷

Clinical Presentation and Diagnosis

The clinical presentation of critical limb ischemia may vary from no symptoms to intermittent claudication, atypical leg pain, rest pain, ischemic ulcers, or gangrene. The ABI is a simple test that can be conducted in the office and typically confirm the presence of disease. It is calculated by dividing the ankle pressure by the highest brachial pressure. An ABI <0.9 is abnormal and indicates critical limb ischemia. An ABI between 0.7 and 0.9 is considered mild disease, between 0.3 and 0.69 is moderate disease, and less than 0.3 is severe disease. There are many classifications for claudication and limb ischemia, but the most utilized is the Rutherford-Becker classification. Rutherford Grade I indicates essentially asymptomatic patients or symptoms during a very high level of activity; Rutherford Grade II is symptoms during a moderate level of activity; and Rutherford Grade III is symptoms during a low level of activity. Claudicants are considered to fall within Rutherford Grade I-III. Rutherford Grade IV is symptoms during rest and is termed "Rest Pain." Rutherford Grade V is forefoot ulceration, and Rutherford Grade VI is ulceration with tissue necrosis. Rutherford Grade V and VI are termed "Tissue Loss."

Claudication is the typical symptomatic expression of critical limb ischemia. However, asymptomatic disease may occur in up to 50% of these patients. Of the 460 patients with critical limb ischemia in the Walking and Leg Circulation Study,¹⁰ 19.8% had no exertional leg pain, 28.5% had atypical leg pain, 32.6% had classic intermittent claudication, and 19.1% had pain at rest. The results of these and other studies indicate that more patients with critical limb ischemia are asymptomatic or have atypical leg symptoms than have classic intermittent claudication.

The presence of critical limb ischemia has two major consequences. The first is a decrease in overall well-being and quality of life due to reduced blood flow and atypical leg pain. This often leads to patients becoming sedentary due to pain and discomfort. They may develop depression. The second consequence is markedly increased cardiovascular morbidity (myocardial infarction and stroke) and mortality (cardiovascular and all-cause).

Risk Factors

Critical limb ischemia is most often diagnosed by an ABI $\leq$ 0.9. A low ABI is an independent predictor of increased mortality. In the Framingham Study, mortality in patients with intermittent claudication was 2–3 times higher than in age- and sex-matched control patients, with 75% of critical limb ischemia patients dying from cardiovascular events. In a 15-year review of patients with claudication, over 66% of mortality was attributable to CVD. In a 10-year prospective study by Criqui et al.,¹¹ critical limb ischemia patients both with and without a history of CVD had a significantly increased risk of dying from cardiovascular and coronary heart disease compared with age-matched control

Figure 2. The relative importance of key risk factors in the progression of peripheral arterial disease.

patients. The all-cause mortality was 3.1 times greater and CVD mortality was 5.9 times greater in patients with critical limb ischemia compared to patients without critical limb ischemia. Studies have shown that the risk of cardiovascular events is similar between critical limb ischemia patients with claudication and those without symptoms. The extremely high morbidity and mortality in the critical limb ischemia population is due to myocardial infarction and stroke. Both the Edinburgh Artery Study¹² and the ARIC (Atherosclerosis Risk in Communities)¹³ study correlated an increased risk of stroke and transient ischemic attack with increased severity of critical limb ischemia. The combination of known coronary or cerebrovascular disease and critical limb ischemia has been shown to increase mortality risk. The BARI (Bypass Angioplasty Revascularization Investigation) trial demonstrated that patients with multivessel CAD and critical limb ischemia had a relative risk of death 4.9-times greater than those without critical limb ischemia.^{14, 15} Additionally, in a pooled analysis of eight randomized prospective trials involving 19,867 patients undergoing percutaneous coronary intervention, the 1-year mortality was 5% in patients with critical limb ischemia and coronary disease compared with 2.1% in patients with coronary disease alone ($p < 0.001$).¹⁶

Chronic limb ischemia is strongly associated with cardiovascular risk factors such as cigarette smoking, diabetes mellitus, dyslipidemia, hypertension, and hyperhomocysteinemia (Figure 2).¹⁷⁻¹⁹ Cigarette smoking is associated with a marked increased risk for peripheral atherosclerosis, and 70–90% of patients with chronic limb ischemia are either current or ex-smokers.^{17, 20-22} Follow-up of smokers and ex-smokers at 7 years shows that critical limb ischemia had developed in 16% of smokers but not in ex-smokers.²³ The 10-year incidence of myocardial infarction is five times greater in the smoking group compared to ex-smokers (53% vs. 11%). At 10-year follow-up, cardiovascular-related mortality in the smoking group is more than 50%, three times that of the nonsmoking group.

Elevated cholesterol has been shown in the Framingham study to be a weak but significant increased risk for chronic limb ischemia.²⁰ Lipid profile abnormalities, such as elevated serum triglyceride levels and reduced high-density lipoproteins, have been found in the majority of studies of patients with chronic limb ischemia,²⁴ and there is a strong inverse relationship between high-density lipoprotein levels and chronic limb ischemia severity.²⁵ Lipoprotein (a) levels have been shown to correlate with LDL, cholesterol, fibrinogen levels, and with the severity of critical limb ischemia.²⁶ The Scandinavian Simvastatin Survival Study

(4S) demonstrated that subjects randomized to simvastatin had a 38% reduction in new or worsening claudication compared with subjects randomized to placebo.²⁷ Another study has demonstrated improved walking ability in patients treated with a statin compared to those not on a statin.²⁸

Markers of inflammation have been associated with the development of atherosclerosis and cardiovascular events.^{29,30} In particular, C-reactive protein (CRP) is independently associated with critical limb ischemia, even in patients with normal lipid levels.^{31,32} Higher CRP levels are associated with poorer functioning measures.³³ In the Physicians Health Study, an elevated CRP level was a risk factor for developing symptomatic critical limb ischemia as well as for peripheral revascularization.³⁴ Elevated plasma homocysteine levels are an independent risk factor for critical limb ischemia.³⁵⁻³⁷ Although B-vitamin supplements can lower homocysteine levels, there is minimal evidence that they can help prevent cardiovascular events.^{38,39}

Platelets and their products are known to play a key role in atherosclerosis. Platelet activity has been shown to be 30% higher in patients with peripheral vascular disease even if they are asymptomatic.^{40,41} Not surprisingly, antiplatelet therapy has shown significant reductions in fatal and non-fatal vascular events in 'high-risk' vascular patients, e.g., claudicants.⁴²⁻⁴⁴ The risk reduction for antiplatelet therapy versus placebo in the claudicant population was 46% for nonfatal stroke, 32% for nonfatal myocardial infarction, and 20% for death from a vascular cause. Even "low-risk" patients on antiplatelet therapy have shown small but significant risk reduction. Progression of peripheral atherosclerosis, as measured by angiography, has also been shown to be inhibited in antiplatelet-treated patients.⁴⁵ A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) had a large subgroup of patients with atherosclerotic vascular disease.⁴⁶ Clopidogrel was shown to have a small but significantly greater reduction in vascular morbidity and mortality than aspirin, and there were no major differences in safety profiles between the two drugs. Despite clopidogrel therapy, patients undergoing percutaneous coronary intervention with stenting are at risk of recurrent coronary events. This could be partly explained by a reduced efficacy of clopidogrel to inhibit platelet aggregation, an *ex vivo*-defined phenomenon called clopidogrel nonresponsiveness or resistance. Laboratory clopidogrel nonresponsiveness can be found in approximately 1 in 5 patients. It is inversely correlated with time between clopidogrel loading and determination of nonresponsiveness and loading dose used.⁴⁷

Hemostatic abnormalities are found frequently in critical limb ischemia and may contribute to pathogenesis or be a marker of disease progression.⁴⁸⁻⁵⁰ The presence of the lupus anticoagulant and elevated markers of platelet activation (beta thromboglobulin levels) have been associated with peripheral atherosclerosis.^{51,52} In a study by Gosk-Bierska et al., hemostatic abnormalities were present in diabetic subjects, with greater evidence of thrombin generation than in non-diabetics.⁵³ Clinical studies on patients undergoing peripheral bypass surgery have demonstrated the presence of a definite subset of patients with abnormal coagulation profiles.⁵⁴ After adjusting for age and sex, von Willebrand Factor (vWF), fibrin, D-dimer and urinary fibrinopeptide A are elevated in patients with critical limb ischemia, and the risk for claudication is significantly raised with unit changes in each factor.^{55,56} Enhanced levels of fibrinogen, alpha-1-antitrypsin, thrombin/antithrombin III complex, alpha-2 plasmin inhibitor/plasmin complex, and thrombomodulin were documented in claudicants.⁵⁷ Compared with healthy control subjects, patients with critical limb ischemia show higher t-PA antigen, PAI-1 antigen, and D-dimer levels both

at rest and after exercise. Thrombin formation is enhanced in these patients after submaximal treadmill exercise. Cumulatively, these data suggest that the patients with critical limb ischemia are relatively hypercoagulable. Higher D-dimer levels are associated with poorer functional activity measures,³³ however, the significance of such findings is unknown.^{57,58}

Socio-Economic Effects

Patients with critical limb ischemia have increased functional impairment and increased rates of functional decline compared to those without critical limb ischemia;¹⁰ specifically, they have lower physical activity levels, slower walking speed, poorer balance, and poorer walking endurance.^{10,59} This functional impairment affects quality of life and may lead to an increased prevalence of depressive symptoms that have been observed in patients with critical limb ischemia.⁶⁰ Even patients with critical limb ischemia who are asymptomatic have significantly impaired lower extremity function compared with those who do not have PAD.⁵⁹

The economic burden of critical limb ischemia is considerable. Brahmanandam et al.⁶¹ recently reported that patients with critical limb ischemia who underwent revascularization used more health care services after hospital discharge than did patients with noncritical limb ischemia. These services included home health care and transfers to rehabilitation facilities. Independent predictors for increased health care services utilization include older age, female gender, care at a private hospital, longer length of hospitalization, African American race, highest income quartile, and undergoing amputation or debridement.⁶¹ The cost of clinical care for patients with critical limb ischemia in 1990 was estimated at \$43,000/patient/year.⁶² The mean cost of inpatient hospital treatment during the first 12 months of follow-up in patients undergoing surgical bypass for critical limb ischemia was estimated at £23,322 sterling, which was approximately one-third higher than patients undergoing angioplasty treatment.⁶³ Others have shown that although there is nearly a two-fold difference in initial cost, the cost-savings of endovascular therapy is not realized over time secondary to subsequent reintervention, particularly in critical limb ischemia patients.⁶⁴ Finally, the median cost of managing a patient after amputation is estimated at almost twice that of successful limb salvage.⁶⁵ Thus, critical limb ischemia represents a challenging disease state that is associated with considerable morbidity and mortality and a large financial impact on society.

CONCLUSION

Chronic critical limb ischemia is a significant, often under-recognized facet of atherosclerotic disease that has significant medical and functional consequences. A thorough understanding of the systemic risk factors associated with the disease followed by rapid intervention and interruption of the process is necessary to improve outcomes and prevent limb loss and death.

Conflict of Interest Disclosure: The author has completed and submitted the *Methodist DeBakey Cardiovascular Journal* Conflict of Interest Statement and none were reported.

Funding/Support: The author has no funding disclosures.

Keywords: critical limb ischemia; cardiovascular disease; cardiovascular risk factors; claudication; peripheral arterial disease; amputation

References

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR, on behalf of the TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). *J Vasc Surg*. 2007 Jan;45(1 Suppl):S5-S67.

2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. *JAMA*. 2001 Sep 19;286(11):1317-24.
3. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. *J Am Geriatr Soc*. 1999 Oct;47(10):1255-6.
4. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. *JAMA*. 2006 Jan 11;295(2):180-9.
5. Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liao CS, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *Atherosclerosis*. 2009 Jun;204(2):e86-92.
6. Jämsén TS, Manninen HI, Tulla HE, Jaakkola PA, Matsi PJ. Infringuinal revascularization because of claudication: total long-term outcome of endovascular and surgical treatment. *J Vasc Surg*. 2003 Apr;37(4):808-15.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*. 2001 May 16;285(19):2486-97.
8. Brandman O, Redisch W. Incidence of peripheral vascular changes in diabetes mellitus. *Diabetes*. 1953 May-Jun;2:194-8.
9. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. *Diabetes Care*. 2002 May;25(5):894-9.
10. McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. *JAMA*. 2004 Jul 28;292(4):453-61.
11. Criqui MH, Fronek A, Barrett-Conner E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. *Circulation*. 1985 Mar;71(3):510-5.
12. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. *Int J Epidemiol*. 1991 Jun;20(2):384-92.
13. Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS, et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. *Atherosclerosis*. 1997 May;131(1):115-25.
14. Sutton-Tyrrell K, Rihal C, Sellers MA, Burek K, Trudel J, Roubin G, et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1998 Feb 15;81(4):375-81.
15. Burek KA, Sutton-Tyrrell K, Brooks MM, Naydeck B, Keller N, Sellers MA, et al. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *J Am Coll Cardiol*. 1999 Sep;34(3):716-21.
16. Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. *J Am Coll Cardiol*. 2006 Oct 17;48(8):1567-72.
17. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease, The San Luis Valley diabetes study. *Circulation*. 1995 Mar 1;91(5):1472-9.
18. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle arm index as a marker of atherosclerosis in Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation*. 1993 Sep;88(3):837-45.
19. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA*. 1997 Jun 11;277(22):1775-81.
20. Kannel WB, McGee DL. Update on some epidemiological feature of intermittent claudication: the Framingham Study. *J Am Geriatr Soc*. 1985 Jan;33(1):13-8.
21. Kannel WB, McGee DL, Castelli WP. Latest perspectives on cigarette smoking and cardiovascular disease: the Framingham study. *J Card Rehabil*. 1984;4:267-77.
22. Vogt MT, Cauley JA, Kuller LH, Hulley SB. Prevalence and correlates of lower extremity arterial disease in elderly women. *Am J Epidemiol*. 1993 Mar 1;137:559-68.
23. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. *Acta Med Scand*. 1987;221(3):253-60.
24. Belch J. Medical management of intermittent claudication. In: Greenhalgh RM, editor. *Vascular and endovascular opportunities*. London: WB Saunders; 2000. p. 361-88.
25. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Arterial Study. *Am J Epidemiol*. 1992 Feb 15;135(4):331-40.
26. Cheng SWK, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. *Eur J Vasc Endovasc Surg*. 1997 Jul;14(1):17-23.
27. Pederson TR, Kjekshus J, Pyörälä K, Olsson AG, Cook TJ, Musliner TA, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). *Am J Cardiol*. 1998 Feb 1;81:333-5.
28. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. *Circulation*. 2003 Feb 11;107(5):757-61.
29. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. 2003 Jan 28;107(3):499-511.
30. Wang TJ, Nam BH, Wilson PW, Wolf PA, Levy D, Polak JK, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. *Arterioscler Thromb Vasc Biol*. 2002 Oct 1;22(10):1662-7.
31. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med*. 2000 Mar 23;342(12):836-43.
32. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein fibrinogen homocysteine lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease. *JAMA*. 2001 May 16;285(19):2481-5.

33. McDermott MM, Greenland P, Green D, Guralnik JM, Criqui MH, Liu K, et al. D-dimer, inflammatory markers and lower extremity functioning in patients with and without peripheral arterial disease. *Circulation*. 2003 Jul 1;107(25):3191-8.
34. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. *Circulation*. 1998 Feb 10;97(5):425-8.
35. Valentine RJ, Kaplan HS, Green R, Jacobsen DW, Myers SI, Clagett GP. Lipoprotein(a), homocysteine and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. *J Vasc Surg*. 1996 Jan;23(1):53-61.
36. Hoogeveen FK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. *Arterioscler Thromb Vasc Biol*. 1998 Jan;18(1):133-8.
37. Selhub J, Jacques PF, Bostom AG, D'agostino RB, Wilson PW, Belanger AJ, et al. Association between plasma homocysteine concentrations and extracranial carotid artery stenosis. *N Engl J Med*. 1995 Feb 2;332(5):286-91.
38. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. *N Engl J Med*. 1999 May 13;340(19):1449-54.
39. Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH. Relationship between plasma homocysteine and vitamin status in the Framingham study population: Impact of folic acid fortification. *Public Health Rev*. 2000;28(1-4):117-45.
40. Smith FB, Lowe GD, Fowkes FG, Rumley A, Rumley AG, Donnan PT, et al. Smoking, hemostatic factors and lipid peroxides in a population case controlled study of peripheral arterial disease. *Atherosclerosis*. 1993 Sep;102(2):155-62.
41. Komarov A, Panchenko E, Dobrovolsky A, Karpov Y, Deev A, Titaeva E, et al. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. *Eur Heart J*. 2002 Aug;23(16):1309-16.
42. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *BMJ*. 1994 Jan 8;308(6943):81-106.
43. Collaborative overview of randomized trials of antiplatelet therapy — II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. *BMJ*. 1994 Jan 15;308(6922):159-68.
44. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002 Jan 12;324(7329):71-86.
45. Hess H, Mietasch A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double blind arteriographically controlled trial. *Lancet*. 1985 Feb 23;1(8426):415-9.
46. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE steering Committee. *Lancet*. 1996 Nov 16;348(9038):1329-39.
47. Snoop JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. *Am Heart J*. 2007 Aug;154(2):221-31.
48. Ray SA, Rowley MR, Loh A, Talbot SA, Bevan DH, Taylor RS. Hypercoagulable states in patients with leg ischemia. *Br J Surg*. 1994 Jun;81(6):811-4.
49. Donaldson MC, Weinberg DS, Belkin M, Whittemore AD, Mannick JA. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. *J Vasc Surg*. 1990 Jun;11(6):825-31.
50. Strano A, Hoppensteadt D, Walenga JM, Fareed J, Sabba C, Berardi E, et al. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. *Semin Thromb Hemost*. 1996;22 Suppl 1:35-40.
51. Donaldson MC, Weinberg DS, Belkin M, Whittemore AD, Mannick JA. Screening for hypercoagulable states in vascular surgical practice: a preliminary study. *J Vasc Surg*. 1990 Jun;11(6):825-31.
52. Catalano M, Russo U, Libretti A. Plasma beta-thromboglobulin levels and claudication states in vascular surgical practice: a preliminary study. *Angiology*. 1986;37:339-42.
53. Gosk-Bierska I, Adamiec R, Alexewicz P, Wyokinski WE. Coagulation in diabetic and non-diabetic claudicants. *Int Angiol*. 2002 Jun;21(2):128-33.
54. Ray SA, Rowley MR, Bevan DH, Taylor RS, Dormandy JA. Hypercoagulable abnormalities and postoperative failure of arterial reconstruction. *Eur J Vasc Endovasc Surg*. 1997 Apr;13(4):363-70.
55. Lee AJ, Fowkes FG, Rattray A, Rumley A, Lowe GD. Hemostatic and rheological factors in intermittent claudication: the influence of smoking and extent of arterial disease. *Br J Haematol*. 1996 Jan;92(1):226-30.
56. Johansson J, Egberg N, Johnsson H, Carlson LA. Serum lipoproteins and hemostatic function in intermittent claudication. *Arterioscler Thrombo*. 1993 Oct;13(10):1441-8.
57. Handa K, Takao M, Nomoto J, Oku K, Shirai K, Saku K, et al. Evaluation of the coagulation and fibrinolytic systems in men with intermittent claudication. *Angiology*. 1996 Jun;47(6):543-8.
58. Mustonen P, Lepäntalo M, Lassila R. Physical exertion induces thrombin formation and fibrin degradation in patients with peripheral atherosclerosis. *Arterioscler Thromb Vasc Biol*. 1998 Feb;18(2):244-9.
59. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. *JAMA*. 2001 Oct 3;286(13):1599-606.
60. Arseven A, Guralnik JM, O'Brien E, Liu K, McDermott MM. Peripheral arterial disease and depressed mood in older men and women. *Vasc Med*. 2001 Nov;6:229-34.
61. Brahmanandam SM, Messina LM, Belkin M, Conte MS, Nguyen LL, editors. Determinants of hospital disposition after lower extremity bypass surgery. Paper presented at: Vascular Annual Meeting, Scientific Program; 2009 Jun 11-14; Denver, CO.
62. Hunink MG, Wong JB, Donaldson MC, Meyerovitz ME, deVries J, Harrington DP. Revascularization for femoropopliteal disease: a decision and cost-effectiveness analysis. *JAMA*. 1995 Jul 12;274(2):165-71.
63. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. *Lancet*. 2005 Dec 3;366(9501):1925-34.
64. Stoner MC, Defreitas DJ, Manwaring MM, Carter JJ, Parker FM, Powell CS. Cost per day of patency: understanding the impact of patency and reintervention in a sustainable model of healthcare. *J Vasc Surg*. 2008 Dec;48(6):1489-96.
65. Singh S, Evens L, Datta D, Gaines P, Beard JD. The costs of managing lower limb-threatening ischaemia. *Eur J Vasc Endovasc Surg*. 1996 Oct;12(3):359-62.